How should we manage breast cancer patients with one to three positive lymph nodes and a low recurrence score? It’s a question we often encounter—and struggle with—in the clinic, but it’s also a question we finally know how to answer thanks to the RxPONDER trial. Here to share the trial’s key findings and what it could mean for pre and postmenopausal women is Dr. Lajos Pusztai, Professor of Medicine and Director of Breast Cancer Translational Research at Yale Cancer Center and Yale School of Medicine.